ERBB2 and breast carcinoma: In breast cancer, approximately 50% of cases classified as the hormone receptor-negative HER2-negative (triple-negative) subtype, considered to be the most aggressive subtype of breast cancer, have been shown to exhibit VM through analysis of clinical samples [37].